Newswire (Published: Wednesday, November 22, 2017, Received: Thursday, November 16, 2017, 2:09:07 PM CST)

Word Count: 490

Reports Summarize Prostate Cancer Findings from University of Tokyo (The biological and clinical advances of androgen receptor function in age-related diseases and cancer)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting out of Tokyo, Japan, by NewsRx editors, the research stated, "Hormonal alterations with aging contribute to the pathogenesis of several diseases. Androgens mediate their effects predominantly through binding to the androgen receptor (AR), a member of the ligand-dependent nuclear receptor superfamily."

Our news journalists obtained a quote from the research from the University of Tokyo, "By androgen treatment, AR is recruited to specific genomic loci dependent on tissue specific pioneer factors to regulate target gene expression. Recent studies have revealed the epigenetic modulation by AR-associated histone modifiers and the roles of non-coding RNAs in AR signaling. Androgens are male sex hormone to induce differentiation of the male reproductive system required for the establishment of adult sexual function. As shown by several reports using AR knockout mouse models, androgens also have anabolic functions in several tissues such as bone, muscle and central nervous systems. Notably, AR has a central role in prostate cancer progression. Prostate cancer is the most frequently diagnosed cancer in men. Androgen-deprivation therapy for cancer patients and decline of serum androgen with aging promote several diseases associated with aging and quality of life of older men such as osteoporosis, sarcopenia and dementia. Thus, androgen replacement therapy for treating late onset hypogonadism (LOH) or new epigenetic regulators have the potential to overcome the symptoms caused by the low androgen, although adverse effects for cardiovascular diseases have been reported."

According to the news editors, the research concluded: "Given the increasing longevity and consequent rise of age-related diseases and prostate cancer patients, a more understanding of the AR actions in male health remains a high research priority."

For more information on this research see: The biological and clinical advances of androgen receptor function in age-related diseases and cancer. Endocrine Journal, 2017;64(10):933-946. Endocrine Journal can be contacted at: Japan Endocrine Soc, 75 Yanaginobanba Nishiiru-Masuya-Cho, Sanjou-Dori, Nakagyou-Ku, Kyoto, 604-8111, Japan (see also Oncology - Prostate Cancer).

Our news journalists report that additional information may be obtained by contacting K. Takayama, University of Tokyo, Grad Sch Med, Dept. of Geriatr Med, Tokyo, Japan.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1507/endocrj.EJ17-0328. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Tokyo, Japan, Asia, Proteins, Article Review, Transcription Factors, DNA-Binding Proteins, Drugs and Therapies, Prostatic Neoplasms, Androgen Receptors, Steroid Receptors, Prostate Cancer, Androgens, Oncology, University of Tokyo.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

University of Tokyo the

Places

Eastern Asia
Japan
Asia
Kyoto
Tokyo

Subjects

Science and Technology
      Scientific Research
      Sciences
            Natural Sciences
                  Biology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Endocrine Disorders
            Men's Health Issues
                  Prostate Cancer
            Reproductive Disorders